c45adda2-fffe-4add-8148-01ecf35dd855
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66.631074606434
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- G2M_CHECKPOINT+0.310
- MTORC1_SIGNALING+0.310
- ANGIOGENESIS+0.280
- PANCREAS_BETA_CELLS+0.280
- E2F_TARGETS+0.270
- MITOTIC_SPINDLE+0.260
- ANDROGEN_RESPONSE+0.250
- HEDGEHOG_SIGNALING+0.250
- MYC_TARGETS_V1+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.330
- INTERFERON_GAMMA_RESPONSE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.250
- UV_RESPONSE_UP-0.240
- DNA_REPAIR-0.230
- FATTY_ACID_METABOLISM-0.210
- HEME_METABOLISM-0.190
- P53_PATHWAY-0.190
- ADIPOGENESIS-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR23303761 | — | — | 0.824 |
| 2 | TCGA-22-4593-01A-21R-1820-07 | — | cohortSQ1 | 0.786 |
| 3 | 20110025.TNBC | — | E | 0.780 |
| 4 | TCGA-60-2703-01A-11R-2045-07 | — | cohortSQ1 | 0.776 |
| 5 | 4b3022ba-0232-493c-b3fc-2447e8cf7113 | — | — | 0.774 |
| 6 | C3N-03662 | — | cohortSQ2 | 0.767 |
| 7 | TCGA-D8-A27F-01A-11R-A16F-07 | — | E | 0.748 |
| 8 | TCGA-A7-A13D-01A-13R-A277-07 | — | E | 0.741 |
| 9 | TCGA-CV-7102-01A-11R-2016-07 | — | — | 0.738 |
| 10 | SRR6013587 | — | cohortA3 | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.180 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |